18 results about "Albumin nanoparticles" patented technology

The invention relates to the technical field of biological medicines, and discloses hyaluronic acid modified metal coordination albumin nanoparticles as well as a preparation method and application thereof. The hyaluronic acid modified metal coordination albumin nanoparticle comprises a core and a hyaluronic acid shell layer, wherein the core is formed by self-assembly of an albumin-drug compound, poly-L-aspartic acid and ferric ions through coordination, and the hyaluronic acid shell layer is connected to the surface of the core through coordination or adsorption. According to the hyaluronic acid modified metal coordination albumin nanoparticles as well as the preparation method and the application thereof, the preparation method is simple, convenient and rapid, does not need complex covalent modification, is mild in condition and is easy for large-scale production, and the prepared nanoparticles are uniform in particle size, good in stability and high in stability. In addition, due to the fact that the hyaluronic acid is modified on the surface, the active targeting capacity on CD44 receptor high-expression tumor cells is achieved, the enrichment and treatment effects of the medicine on the tumor site are remarkably improved, and the application prospect in preparation of the anti-tumor medicine is wide.

The present application belongs to the technical field of medicine, and particularly relates to albumin nanoparticles co-loading paclitaxel and BMS-202, a preparation method and application thereof. The present application comprises a carrier and a delivery carrier loaded with drugs; comprises a carrier and drugs loaded by a delivery carrier; the drugs are paclitaxel and an inhibitor BMS-202 co-loaded with paclitaxel, and the delivery carrier is human serum albumin. The present application comprises the following steps: step 1: paclitaxel and the inhibitor BMS-202 are dissolved in an organic solvent as an organic phase; step 2: human serum albumin is dissolved in water as an aqueous phase; step 3: the organic phase is directly added to the aqueous phase, and after mixing, ultrasonic treatment is immediately performed to make the system form a nanoparticle suspension; step 4: the nanoparticle suspension is subjected to purification treatment to remove the organic solvent and unencapsulated drugs, and albumin nanoparticles co-loading paclitaxel and BMS-202 are obtained. The present application is applied to the preparation of esophageal squamous cell carcinoma drugs. Compared with the prior art, the present application is relatively effective and safe in the treatment of esophageal cancer.

The invention relates to a cathepsin B sensitive fatty acid-adriamycin prodrug as well as albumin nanoparticles, a preparation method and application thereof, and belongs to the technical field of medicines. The cathepsin B sensitive fatty acid-adriamycin prodrug is a prodrug as shown in a formula (I), a geometric isomer thereof, and pharmaceutically acceptable salts, hydrates and solvates thereof, wherein n is equal to 0-14. The invention also relates to a combined albumin nanoparticle prepared by entrapping the cathepsin B sensitive fatty acid-adriamycin prodrug by using human / bovine serum albumin as a carrier. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, and release a parent drug adriamycin after being taken by tumor cells and hydrolyzed by cathepsin B; therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to manganese-based paclitaxel albumin nanoparticles as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, adding paclitaxel into absolute ethyl alcohol to form a paclitaxel-ethyl alcohol mixture with the concentration of 1mg / mL; s2, adding PEG (Polyethylene Glycol) into the paclitaxel-ethanol mixture, carrying out vortex mixing uniformly, and removing an organic solvent in the paclitaxel-ethanol mixture through rotary evaporation to obtain a mixed solution of paclitaxel and PEG; s3, adding HSA into the mixed solution of the paclitaxel and the PEG to enable the mixed solution not to be in a flowing state, so as to obtain a semi-solid mixture of the paclitaxel and the PEG; and S3, adding a KMnO4 solution into the semi-solid mixture obtained by mixing paclitaxel and PEG, uniformly mixing, and then carrying out ultrasonic treatment to obtain the manganese-based paclitaxel albumin nanoparticles (PTX-HSA-MnO2NPs). And the preparation process can meet the requirements of green industrial production.

This invention provides a method for the continuous preparation of paclitaxel albumin nanoparticles, comprising the following steps: A) Paclitaxel raw material is fed into an emulsification device at a first rate of 80-90 ml / min; albumin aqueous solution is fed into the emulsification device at a second rate of 3-4 L / min; B) Paclitaxel raw material and albumin aqueous solution are emulsified and sheared to complete drug loading, thus obtaining the nanoparticles. In this method, the paclitaxel organic solvent and human serum albumin aqueous solution are continuously introduced, allowing for continuous emulsification and shearing. The emulsification and shearing effect is consistent every minute, and the production batch size is only related to time. The batch size is determined by controlling the emulsification and shearing time, and the product uniformity is not affected by the batch size. This invention solves the problem that current paclitaxel nanoparticle preparation processes cannot achieve continuous manufacturing, improving system flexibility; and addresses the problems of batch dependence on equipment and difficulty in batch expansion.

The invention belongs to the technical field of medicines, and relates to Torin 1 albumin nanoparticles attached to the surfaces of red blood cells, a preparation method of the Torin 1 albumin nanoparticles and application of the Torin 1 albumin nanoparticles in acute lung injury. The preparation method comprises the following steps: self-assembling an indissolvable mTOR kinase inhibitor Torin1 and bovine serum albumin to form drug-loaded nanoparticles, homogenizing the drug-loaded nanoparticles, and attaching the drug-loaded nanoparticles to the surfaces of red blood cells to obtain RBC-Torin1-coated BSA. The system can improve the problem of poor solubility of Torin1, reduce nonspecific removal of nano-particles, improve distribution and enrichment of the nano-particles in lung tissues, and enhance the treatment effect on acute lung injury.

The application belongs to the technical field of biological medicine material preparation, and particularly relates to albumin nanoparticles loaded with ferroptosis related drugs and a preparation method thereof. The ferroptosis related drug composition comprises porphyrin drugs, unsaturated fatty acid drugs-cystamine and sulfosuccinimidyl oleate (SSO). The porphyrin drugs, the unsaturated fatty acid drugs-cystamine and the SSO are slowly added dropwise into an albumin solution under stirring, the drugs enter the hydrophobic cavities of the albumin, and uniform nanoparticles are spontaneously formed. The obtained nanoparticles are small in size and uniform, can efficiently deliver drugs through passive targeting mediated by the EPR effect and active targeting mediated by the Gp60-Caveola-SPARC pathway, improve stability, reduce accumulation at non-target sites and systemic toxicity, amplify the effect of ferroptosis after combination compared with the ferroptosis related drugs used alone, and thus produce a synergistic anti-tumor effect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to human serum albumin nanoparticles entrapped with alpha-mangostin as well as a preparation method and application of the human serum albumin nanoparticles. The alpha-M entrapped human serum albumin nanoparticles provided by the invention comprise an alpha-M raw material medicine and human serum albumin (HSA), the preparation method comprises the following four steps: high-pressure homogenization, rotary evaporation, degerming filtration and freeze drying. The nano delivery system has good safety and stability, and is proved to have multiple effects of immunoregulation, tumor invasion and metastasis inhibition, matrix barrier weakening and the like at cellular level and animal level; the compound can be used for preparing anti-tumor drugs including pancreatic cancer, breast cancer, colon cancer and the like, can be used for effectively inhibiting tumor progression when being combined with chemotherapy drugs, and has broad-spectrum anti-cancer application value.

This invention relates to a cathepsin B-sensitive fatty acid-doxacin prodrug, its albumin nanoparticles, preparation method, and application, belonging to the field of pharmaceutical technology. The cathepsin B-sensitive fatty acid-doxacin prodrug is defined as the prodrug shown in general structural formula (I), its geometric isomers, and its pharmaceutically acceptable salts, hydrates, and solvates; where n = 0-14. Further, the cathepsin B-sensitive fatty acid-doxacin prodrug is encapsulated using human / bovine serum albumin as a carrier to prepare bound albumin nanoparticles. These albumin nanoparticles have a small and uniform particle size, exhibiting good placement and colloidal stability. They remain stable in systemic circulation and normal tissues. However, after being taken up by tumor cells, they are hydrolyzed by cathepsin B to release the parent drug doxacin, thereby achieving specific killing of tumor cells without producing serious toxic side effects, showing promising clinical development prospects.

The invention relates to a CES1 / CES2 cascade activated camptothecin-fatty alcohol prodrug and albumin nanoparticles thereof as well as a preparation method and application thereof, and belongs to the technical field of medicines. The CES1 / CES2 cascade activated camptothecin-fatty alcohol prodrug is a prodrug as shown in a formula (I) or a pharmaceutically acceptable salt of the prodrug. The invention also relates to a combined albumin nanoparticle prepared from the camptothecin-fatty alcohol prodrug entrapped with CES1 / CES2 cascade activation. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, can release an intermediate through CES1-mediated primary hydrolysis after being taken by tumor cells, and then the intermediate is subjected to secondary hydrolysis under the action of CES2 to release a parent drug camptothecin, so that the curative effect of the camptothecin on tumor cells is improved, and the curative effect of the camptothecin on tumor cells is improved. Therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved. Formula (I)

This invention provides a biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions, its preparation method, and its application. The biomimetic nanoparticle composite PRP hydrogel is formed by cross-linking a hydrogel matrix and composite nanoparticles dispersed therein. The core of the composite nanoparticles is albumin nanoparticles loaded with macrophage migration inhibitory factor inhibitors, and the outer shell of the composite nanoparticles is a fibroblast membrane. The preparation method includes the following steps: preparing a composite nanoparticle dispersion; mixing sodium alginate with the composite nanoparticle dispersion to prepare a sodium alginate solution; adding platelet-rich plasma and mixing evenly; adding calcium carbonate and an acidity regulator; stirring evenly and allowing to stand to form a gel, thus obtaining the biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions.

The present application belongs to the technical field of biological medicine, and particularly relates to a sodium alginate microsphere co-loading nano-gold probiotics and curcumin albumin nanoparticles and preparation and application thereof. The present application synthesizes nano-gold by modifying probiotics Escherichia coli Nissle 1917, prepares curcumin albumin nanoparticles by using the principle of self-assembly, and then prepares the sodium alginate microsphere co-loading nano-gold probiotics and curcumin albumin nanoparticles by using the method of high-voltage electrostatic, which is used for the treatment of inflammatory bowel disease. Compared with the traditional preparation of nano-gold, the present application proposes a new green synthesis method, while keeping the activity of probiotics. In order to improve the problem of poor water solubility of curcumin, the present application uses albumin to load drugs, prepares curcumin albumin nanoparticles, and then combines with the sodium alginate microsphere, which has colon targeting, improves the bioavailability of probiotics and curcumin, and is effectively used for the treatment of inflammatory bowel disease.

This invention discloses albumin nanoparticles co-loaded with flavin and lactate oxidase, their preparation method, and applications. Using human serum albumin as a carrier, flavin and lactate oxidase are simultaneously encapsulated at a mass ratio of 10:1, with a particle size of 150-180 nm and a polydispersity index of less than 0.2. This invention exerts its anti-hepatocellular carcinoma effect through mechanisms such as reducing lactate levels in the tumor microenvironment, inducing an increase in reactive oxygen species, inhibiting cGAS protein lactation modification, and activating the cGAS-STING signaling pathway. The nanoparticles exhibit high encapsulation efficiency and good stability. The flavin loaded on these nanoparticles can significantly reduce the reduction of pyruvate to lactate by inhibiting lactate dehydrogenase; simultaneously, the lactate oxidase loaded on these nanoparticles catalyzes the dehydrogenation of lactate to pyruvate. In other words, these nanoparticles synergistically regulate lactate metabolism through a two-way regulatory strategy of "reducing source and increasing sink"—"inhibiting lactate production" and "promoting lactate clearance"—significantly enhancing in vitro and in vivo anti-tumor effects, and demonstrating high biosafety.

The application discloses a pH-responsive deformable double-targeting nano-protein and a preparation method and application thereof, and the method comprises the following steps: after carboxylated mannose is activated through an EDC / NHS system, the carboxylated mannose is reacted with an albumin solution, and mannose-modified albumin is obtained through dialysis purification; the mannose-modified albumin is mixed with an inhibitor IRG1-IN-1, and IRG1-IN-1 is loaded through hydrophobic interaction to obtain mannose albumin nanoparticles; ferritin is used as a carrier, and oxaliplatin is loaded through a solvent displacement method to obtain ferritin nanoparticles; CHO-PEG2k-CHO is used as a connecting agent, and the mannose albumin nanoparticles and the ferritin nanoparticles are crosslinked through a Schiff base reaction to form large-size pH-responsive double-targeting nano-proteins. The double-targeting separable characteristics of the nano-proteins can realize specific treatment, kill tumor cells, interfere with immune cell metabolism, block metabolic immunosuppression, and promote anti-tumor immunotherapy.

The invention relates to a cathepsin B sensitive fatty acid-avitecan prodrug, albumin nanoparticles thereof, a preparation method and application, and belongs to the technical field of medicines. The cathepsin B-sensitive fatty acid-avitecan prodrug is a prodrug as shown in a formula (I), a geometric isomer of the prodrug, and pharmaceutically acceptable salts, hydrates and solvates of the prodrug, wherein n is equal to 0-14. The invention also relates to a combined albumin nanoparticle prepared by using human / bovine serum albumin as a carrier to encapsulate a cathepsin B sensitive fatty acid-etiotecan prodrug. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, and release a parent drug, namely avixetecan after being taken by tumor cells and hydrolyzed by cathepsin B, so that the albumin nanoparticles can be used for treating tumor tumors. Therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved.

The present invention provides an albumin nanoparticle, comprising: a neoantigen peptide conjugated to an albumin hitchhiking compound to form a conjugated compound; and a plurality of albumins; wherein the conjugated compound is non-covalently bonded to the plurality of albumins via the albumin hitchhiking compound; wherein the plurality of albumins are non-covalently bonded and covalently crosslinked to each other; and wherein the conjugated compound is configured to be released from the albumin nanoparticle when subjected to pH 6 and below.

The application discloses atorvastatin calcium albumin nanoparticles and a preparation method and application thereof. The atorvastatin calcium albumin nanoparticles are composed of atorvastatin calcium and serum albumin, and the mass ratio of atorvastatin calcium to serum albumin is 1:3-1:10. The preparation method comprises the following steps: weighing atorvastatin calcium, fully dissolving the atorvastatin calcium in anhydrous ethanol to obtain an organic phase; weighing serum albumin, fully dissolving the serum albumin in deionized water, adjusting the pH of the solution by sodium hydroxide to obtain an aqueous phase; under stirring, dropping the organic phase into the aqueous phase, adding glutaraldehyde solution, continuously stirring and crosslinking, after the crosslinking is completed, removing the anhydrous ethanol by rotary evaporation, centrifuging the obtained solution by using a high-speed refrigerated centrifuge, and taking the lower precipitate as the atorvastatin calcium albumin nanoparticles. The atorvastatin calcium albumin nanoparticles prepared in the application can prolong the in-vivo circulation time of atorvastatin calcium, improve the bioavailability, and especially improve the antitumor activity of atorvastatin calcium.

The invention discloses composite paclitaxel albumin nanoparticles as well as a preparation method and application thereof, paclitaxel and a non-nucleotide interferon gene stimulating factor agonist are co-loaded by human serum albumin in a simple manner to form nanoparticles which are uniform in size, proper in particle size, relatively good in dispersity and stable in physicochemical property; the added non-nucleotide interferon gene stimulating factor agonist forms a dimer in a tumor acidic microenvironment, and active targeting of the carrier is combined, so that the nanoparticles have excellent selectivity on tumor tissues; a non-nucleotide interferon gene stimulating factor agonist starts congenital immunity and is combined with adaptive immunity of paclitaxel, so that the defect of low immune responsiveness of'cold 'tumors is overcome. In-vivo and in-vitro toxicity experiments prove that the nanoparticles provided by the invention can solve the problem of strong toxic and side effects of paclitaxel and have synergistic effects on anti-tumor immunotherapy of paclitaxel at the same time, so that the effect of combined treatment is achieved.